Skip to main content
    A

    Avalo Therapeutics Inc (AVTX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $12.01
    +0.17 (+1.44%)

    Market Cap: $644.10M

    Last updated: Oct 16, 2026 at 1:54 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    53%(20/38)
    Avg Surprise
    -373.32%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.56
    Range$-0.66 - $-0.45
    8 analysts
    EPS Revisions
    3
    0
    7d
    3
    2
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.55-2.1%
    60d ago$-0.55-2.1%
    30d ago$-0.56-0.4%
    7d ago$-0.56-0.4%
    Current$-0.56
    Revenue Consensus
    $0
    Range$0 - $0
    11 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.54
    Range$-0.87 - $0.01
    8 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    12 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.54---
    Sep 26EST
    		-$-0.56---
    Jun 26
    Reported Aug 6
    		$-0.83$-0.66-25.76%Miss+56.8%
    Mar 26
    Reported May 13
    		$-0.98$-1.03+4.85%Beat+21.6%
    Dec 25
    Reported Mar 23
    		$-0.37N/A+75.25%Beat+86.5%
    Sep 25
    Reported Nov 6
    		$-2.19$-1.64-33.54%Miss-323.5%
    Jun 25
    Reported Aug 7
    		$-1.92$-1.43-34.27%Miss-145.6%
    Mar 25
    Reported Apr 4
    		$-1.25$-1.60+21.88%Beat+99.1%
    Dec 24
    Reported Mar 27
    		$-2.74$1.67-264.56%Miss+97.6%
    Sep 24
    Reported Nov 7
    		$0.98$-1.19+182.35%Beat+103.7%
    Jun 24
    Reported Jul 11
    		$4.21$-6.70+162.84%Beat+103.0%
    Mar 24
    Reported May 13
    		$-141.00$-1.18-11849.15%Miss-16488.2%
    Dec 23
    Reported Mar 28
    		$-116.21$-4.80-2321.04%Miss+53.4%
    Sep 23
    Reported Nov 9
    		$-26.40N/A+90.00%Beat-132.4%
    Jun 23
    Reported Aug 3
    		$-141.60$-168.00+15.71%Beat+57.2%
    Mar 23
    Reported May 4
    		$-0.85$-0.97+12.37%Beat+64.6%
    Dec 22
    Reported Mar 29
    		$-249.60$-156.00-60.00%Miss+45.8%
    Sep 22
    Reported Nov 7
    		$81.60N/A+125.89%Beat+116.7%
    Jun 22
    Reported Aug 4
    		$-331.20$-424.80+22.03%Beat+36.1%
    Mar 22
    Reported May 5
    		$-2.40$-1.60-50.00%Miss+37.5%
    Dec 21
    Reported Mar 2
    		$-460.80$-439.20-4.92%Miss+5.9%
    Sep 21
    Reported Nov 9
    		$-489.60$-518.40+5.56%Beat-6.3%
    Jun 21
    Reported Aug 2
    		$-518.40$-508.80-1.89%Miss-9.6%
    Mar 21
    Reported May 13
    		$-3.84$-2.32-65.52%Miss+98.4%
    Dec 20
    Reported Mar 8
    		$-489.60$-432.00-13.33%Miss-136100.0%
    Sep 20
    Reported Nov 9
    		$-460.80$-273.60-68.42%Miss-116.1%
    Jun 20
    Reported Aug 6
    		$-472.89$-302.40-56.38%Miss-61.6%
    Mar 20
    Reported May 7
    		$-247.39$-355.20+30.35%Beat+31.8%
    Dec 19
    Reported Mar 11
    		$0.36N/A-57.14%Miss+116.7%
    Sep 19
    Reported Nov 14
    		$-213.23$-388.80+45.16%Beat+89.6%
    Jun 19
    Reported Aug 8
    		$-292.61$-470.40+37.80%Beat+46.5%
    Mar 19
    Reported May 9
    		$-362.88$-470.40+22.86%Beat-14.5%
    Dec 18
    Reported Mar 18
    		$-2.16$-0.60-260.00%Miss-100.1%
    Sep 18
    Reported Nov 13
    		$-2044.78$-345.60-491.66%Miss-407.1%
    Jun 18
    Reported Aug 9
    		$-547.20$-288.00-90.00%Miss-23900.0%
    Mar 18
    Reported Apr 2
    		$-316.80N/A+52.17%Beat+42.4%
    Sep 17
    Reported Nov 6
    		$1497.59$-374.40+500.00%Beat-
    Jun 17
    Reported Aug 14
    		$-403.20$-633.60+36.36%Beat-
    Mar 17
    Reported May 9
    		$-2.28$-4.44+48.65%Beat-
    Dec 16
    Reported Mar 14
    		$-549.85N/A+69.21%Beat-

    Key Metrics

    Valuation
    P/E Ratio-2.75EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin-154847.00%
    ROE-36.30%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio19.31xQuick Ratio19.31x
    Trading Statistics
    Beta0.69Avg Volume1.12M
    52-Week High$24.2752-Week Low$11.58

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$13.29
    SMA 20$14.48
    SMA 50$17.13
    SMA 200$16.48
    EMA 10$13.17
    EMA 20$14.29
    EMA 50$16.02
    EMA 200$16.01

    MACD

    Line: -1.39Signal: -1.20Hist: -0.19

    ADX

    ADX: 47.0+DI: 9.0-DI: 39.1

    Aroon & PSAR

    Aroon Up4.0
    Aroon Down96.0
    PSAR$14.62

    Bollinger Bands

    Upper Band$17.43
    Lower Band$11.53
    %B Position4079%(Upper)
    Band Width0.08

    RSI (14-Day)

    Oversold
    23.8

    Momentum Oscillators

    Stoch %K5.4
    Stoch %D7.8
    Williams %R-90.2
    ROC (10d)-19.7%
    Momentum-2.94
    CCI (20d)-136.1
    MFI (14d)32.8

    Volatility Measures

    ATR (14d)$0.86(7.2%)
    StdDev (20d)1.48
    Hist Vol52.6%(High)

    Volume Flow

    VWAP$12.02
    OBV18.3M
    AD Line-12.5M
    CMF (20d)-0.128

    Volume Metrics

    Avg Vol (20d)1.1M
    Vol Ratio0.8x
    VWMA (20d)$14.67

    Pivot Points

    R3$12.65
    R2$12.39
    R1$12.11
    Pivot Point$11.85
    S1$11.57
    S2$11.31
    S3$11.03

    Advanced Oscillators

    TSI-45.09
    Ultimate Osc39.3
    KST-239.82

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$59,000$0$0$0$192,000$249,000$0$0$570,000$236,000
    Cost of Revenue$0$0$16,000$0$0$0$85,000$-714,000$343,000$-80,000$-222,000$247,000
    Gross Profit$0$0$59,000$0$0$0$107,000$963,000$-343,000$80,000$792,000$-11,000
    Operating Expenses$31.52M$20.90M$19.80M$19.20M$19.32M$14.67M$13.42M$13.82M$9.23M$32.85M$8.45M$3.74M
    R&D$23.42M$14.05M$13.27M$13.62M$14.07M$9.12M$8.18M$9.54M$4.70M$29.65M$1.87M$1.25M
    SG&A$8.10M$6.85M$6.54M$5.58M$5.24M$5.55M$5.23M$4.29M$4.53M$3.19M$2.67M$2.49M
    Operating Income$-31,517,000$-20,901,000$-19,742,000$-19,198,000$-19,316,000$-14,669,000$-13,309,000$-12,861,000$-9,575,000$-32,767,000$-7,659,000$-3,750,000
    Interest Income$2.76M$803,000$984,000$1.12M$1.10M$1.15M$1.21M$964,000$1.04M$100,000$81,000$-1,553,000
    Interest Expense$4.82M$0$0$11.42M$1.43M$0$21.92M$0$0$88.52M$518,000$1.47M
    Income Before Tax$-36,340,000$-19,618,000$-13,590,000$-30,614,000$-20,749,000$-13,141,000$-35,225,000$23.02M$98.47M$-121,283,000$-8,177,000$-5,220,000
    Income Tax Expense$18,000$12,000$130,000$11,000$16,000$8,000$114,000$-14,000$7,000$7,000$-9,000$8,000
    Net Income$-36,358,000$-19,630,000$-13,720,000$-30,625,000$-20,765,000$-13,149,000$-35,339,000$23.04M$98.46M$-121,290,000$-8,168,000$-5,228,000
    EBITDA$-39,502,000$-20,510,000$-14,755,000$-32,019,000$-21,858,000$-14,154,000$-36,366,000$22.09M$97.46M$-121,349,000$-8,215,000$-2,497,000
    EBIT$-39,101,000$-20,421,000$-14,574,000$-31,731,000$-21,846,000$-14,289,000$-36,434,000$22.06M$97.43M$-121,383,000$-8,258,000$-3,667,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about AVTX

    News

    Avalo Therapeutics, Inc. (C6K0.F) Analyst Insights, Price Targets & Recommendations

    This article provides an overview of analyst insights, price targets, and recommendations for Avalo Therapeutics...

    Yahoo! Finance Canada•10/9/26•Neutral

    Trading the Move, Not the Narrative: (AVTX) Edition

    This article provides an AI-generated analysis for Avalo Therapeutics Inc. (NASDAQ: AVTX), noting weak near and mid-term sentiment with a neutral long-term outlook and elevated downside risk. It outlines three distinct...

    Stock Traders Daily•10/7/26•Somewhat-Bearish

    In lieu of Board fees, Avalo Therapeutics (AVTX) grants Rita Jain 1,322 fully vested stock options.

    Avalo Therapeutics (AVTX) director Rita Jain was granted 1,322 fully vested stock options on September 30, 2026, as compensation for Board fees. These options have an exercise price of $15.33 per share...

    Stock Titan•10/2/26•Neutral

    In lieu of board fees, Avalo Therapeutics (AVTX) grants Ron M. Philip 1,109 stock options.

    Avalo Therapeutics (AVTX) director Ron M. Philip was granted 1,109 stock options on September 30, 2026, in lieu of Board fees. These options were 100% vested on the grant date, have an exercise price of $15.33...

    Stock Titan•10/2/26•Neutral

    1,352 fully vested options replace Board fees for Avalo Therapeutics (AVTX) director Kevin Robert Lind.

    Avalo Therapeutics director Kevin Robert Lind was granted 1,352 fully vested stock options on September 30, 2026...

    Stock Titan•10/2/26•Neutral

    AVTX Valuation and Fair Value

    P/E
    -2.7x
    P/B
    1.2x
    See GNG's fair value

    AVTX Profitability: Margins, ROIC and FCF

    Operating margin
    -154847.0%
    Net margin
    0.0%
    ROE
    -36.3%
    FCF margin
    -115745.8%

    AVTX Competitors

    CompanyTicker
    Phreesia IncPHR
    Performant Healthcare, IncPHLT
    OmniAb Inc.OABI
    Pacific Biosciences of CaliforniaPACB
    Pharming Group NVPHAR
    SurModics IncSRDX
    4D Molecular Therapeutics IncFDMT
    Zevra Therapeutics Inc.ZVRA

    Sector: Healthcare

    AVTX Analyst Ratings

    Consensus
    Buy
    Analysts
    14
    Strong Buy
    2
    Buy
    12
    Hold
    0
    Sell
    0
    Strong Sell
    0

    AVTX Bull Case vs Bear Case

    Bull case

    • 100.0% of AVTX's analyst ratings are Buy or Strong Buy.

    Bear case

    • AVTX's quarterly revenue changed -69.3% year over year.

    AVTX Earnings: Beat Rate and Next Report

    Beat rate
    4 of 8 quarters (50.0%)
    Average surprise
    -9.2%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.56
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    3 up, 2 down

    Frequently Asked Questions About AVTX

    Does AVTX pay dividends?

    Avalo Therapeutics Inc (AVTX) does not currently pay a regular dividend.

    What is AVTX's market cap?

    Avalo Therapeutics Inc (AVTX) has a market capitalization of $644.10M with a current stock price of $12.01.

    Related stocks

    Sector: Healthcare

    All stocks starting with A

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In